Theravance Biopharma Statistics
Total Valuation
TBPH has a market cap or net worth of $495.01 million. The enterprise value is $401.51 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TBPH has 50.00 million shares outstanding. The number of shares has decreased by -4.72% in one year.
| Current Share Class | 50.00M |
| Shares Outstanding | 50.00M |
| Shares Change (YoY) | -4.72% |
| Shares Change (QoQ) | +2.00% |
| Owned by Insiders (%) | 5.51% |
| Owned by Institutions (%) | 40.51% |
| Float | 22.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 72.14 |
| PS Ratio | 7.46 |
| Forward PS | 4.94 |
| PB Ratio | 2.96 |
| P/TBV Ratio | 2.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.77, with a Debt / Equity ratio of 0.23.
| Current Ratio | 4.77 |
| Quick Ratio | 4.64 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.84 |
Financial Efficiency
Return on equity (ROE) is -31.46% and return on invested capital (ROIC) is -12.51%.
| Return on Equity (ROE) | -31.46% |
| Return on Assets (ROA) | -7.98% |
| Return on Invested Capital (ROIC) | -12.51% |
| Return on Capital Employed (ROCE) | -14.63% |
| Revenue Per Employee | $672,845 |
| Profits Per Employee | -$601,371 |
| Employee Count | 97 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TBPH has paid $9.98 million in taxes.
| Income Tax | 9.98M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.77% in the last 52 weeks. The beta is -0.10, so TBPH's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | +3.77% |
| 50-Day Moving Average | 9.28 |
| 200-Day Moving Average | 9.03 |
| Relative Strength Index (RSI) | 58.86 |
| Average Volume (20 Days) | 241,035 |
Short Selling Information
The latest short interest is 3.60 million, so 7.20% of the outstanding shares have been sold short.
| Short Interest | 3.60M |
| Short Previous Month | 3.57M |
| Short % of Shares Out | 7.20% |
| Short % of Float | 15.81% |
| Short Ratio (days to cover) | 17.05 |
Income Statement
In the last 12 months, TBPH had revenue of $65.27 million and -$58.33 million in losses. Loss per share was -$1.19.
| Revenue | 65.27M |
| Gross Profit | 25.14M |
| Operating Income | -45.66M |
| Pretax Income | -38.22M |
| Net Income | -58.33M |
| EBITDA | -43.60M |
| EBIT | -45.66M |
| Loss Per Share | -$1.19 |
Full Income StatementBalance Sheet
The company has $130.86 million in cash and $37.35 million in debt, giving a net cash position of $93.51 million or $1.87 per share.
| Cash & Cash Equivalents | 130.86M |
| Total Debt | 37.35M |
| Net Cash | 93.51M |
| Net Cash Per Share | $1.87 |
| Equity (Book Value) | 165.98M |
| Book Value Per Share | 3.34 |
| Working Capital | 118.76M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 38.52%, with operating and profit margins of -69.96% and -89.38%.
| Gross Margin | 38.52% |
| Operating Margin | -69.96% |
| Pretax Margin | -74.08% |
| Profit Margin | -89.38% |
| EBITDA Margin | -66.81% |
| EBIT Margin | -69.96% |
| FCF Margin | n/a |